Elrexfio (Elranatamab-bcmm)

Elrexfio (elranatamab-bcmm) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager used for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least 4 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.

Recommended Dosage: The recommended dosages of Elrexfio subcutaneous (SC) injection are: step-up dose 1 of 12 mg on Day 1, step-up dose 2 of 32 mg on Day 4, followed by the first treatment dose of 76 mg on Day 8, and then 76 mg weekly thereafter through week 24. For those who have received at least 24 weeks of treatment with Elrexfio and have achieved a response [partial response (PR) or better] and maintained this response for at least 2 months, the dosing interval should transition to an every 2-week schedule.

Continue therapy with Elrexfio injection until disease progression or unacceptable toxicity. Administer pre-treatment medications before each dose in the Elrexfio step-up dosing schedule, which includes step-up dose 1, step-up dose 2, and the first treatment dose as recommended. 

• Elrexfio can cause CRS, including hazardous or fatal reactions. Start treatment as per the step-up dosing schedule to reduce the risk of CRS and monitor patients after the administration of Elrexfio accordingly. Administer pre-treatment medicines before each dose in the step-up dosing schedule to minimize the risk of CRS.
  
• Elrexfio 76 mg/1.9 mL can cause severe or life-threatening neurologic toxicity, including ICANS. Monitor patients for signs and symptoms of neurologic toxicities during therapy with Elrexfio. At the first sign of neurologic toxicity, including ICANS, assess and treat patients promptly based on severity.
  
• Elrexfio can cause serious, life-threatening, or fatal infections. Avoid initiating this treatment in patients with active infections. Monitor patients for signs and symptoms of infection before and during treatment and treat them appropriately. Withhold or permanently stop treatment on behalf of severity.
  
• Elranatamab-bcmm can cause hepatotoxicity. Liver enzyme elevation may occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and throughout treatment. Withhold treatment or consider permanent discontinuation of treatment based on severity.
  
• Based on its mechanism of action, Elranatamab-bcmm may cause fetal harm when administered to a pregnant woman. Females of reproductive age should use effective contraception during treatment and for 4 months after the final dose

What documents are required to import ELREXFIO to India?

ELREXFIO (elranatamab-bcmm) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable
  

Is ELREXFIO available in India?

ELREXFIO (elranatamab-bcmm injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Elrexfio in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

ELREXFIO can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ELREXFIO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Elrexfio 76 mg/1.9 mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Elrexfio®?

Elranatamab-bcmm is a Generic Name for the trade name drug Elrexfio®.

What is the Manufacturer’s Name of Elrexfio®?

Elrexfio® is manufactured by Pfizer Inc.

Is Elrexfio® approved by the FDA?

Yes, Elrexfio® is approved by the FDA. Date of first approval: August 14, 2023.

Where can I get Elrexfio® at the best price in India?

To get the best Elrexfio 44 mg/1.1 mL price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Elrexfio®, a medical prescription is needed from a treating physician.

What is the dosage and form of Elrexfio® supplied?

Elrexfio® is supplied as Injections: 76 mg/1.9 mL (40 mg/mL) and 44 mg/1.1 mL (40 mg/mL) in a single-dose vial for subcutaneous use. 

What are the most common side effects of Elrexfio®? 

The most common side effects of Elrexfio® are fatigue, CRS, diarrhea, upper respiratory tract infection, injection site reaction, musculoskeletal pain, pneumonia, rash, cough, decreased appetite, nausea, and pyrexia. 

How much does Elrexfio® cost in India?

The cost of Elrexfio in India can vary. To procure this BCMA-directed CD3 T-cell engager legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Elrexfio®?

Store refrigerated at 2 to 8 °C (36 to 46 °F) in the original carton until the time of use to protect it from light. Do not freeze or shake the vial or carton. 

Is it safe to buy Elrexfio® online in India?

Yes, one can buy Elrexfio online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Elrexfio® through legal channels.